Evotec AG (ETR:EVT) has been given a €13.00 ($15.29) price target by Berenberg Bank in a research report issued on Thursday. The brokerage presently has a “neutral” rating on the stock.
Separately, Deutsche Bank AG set a €16.00 ($18.82) price objective on shares of Evotec AG and gave the company a “buy” rating in a report on Monday.
Shares of Evotec AG (ETR:EVT) opened at 14.024 on Thursday. The stock has a 50 day moving average of €13.26 and a 200-day moving average of €10.68. Evotec AG has a one year low of €4.14 and a one year high of €14.65. The company has a market capitalization of €1.96 billion and a price-to-earnings ratio of 55.431.
About Evotec AG
Evotec AG provides drug discovery solutions to the pharmaceutical and biotechnology companies, academic institutions, and foundations and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services.
Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.